A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy.
Interindividual genetic profile differences related to antipsychotic drug therapy may be determined based on molecular genetic studies of the pathogenesis of schizophrenia and studies of antipsychotic drug responses (therapeutic as well as adverse responses). In the present article, we review molecular genetic studies of tardive dyskinesia (TD), which is a representative adverse response to antipsychotic drugs. Such studies have been performed to explore the gene-associated pharmacokinetic and pharmacodynamic processes of antipsychotic drugs. Positive associations between several genes and TD have been reported. The accumulation of results from such studies will hopefully lead to individualized antipsychotic drug therapies that involve the application of new genomic techniques, including DNA microarrays. Subsequently, antipsychotic drugs may in the future be prescribed for smaller subgroups of patients who have been classified as having a particular genetic profile.
Ohmori
Osamu
O
Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. o-ohmori@med.uoeh-u.ac.jp
Shinkai
Takahiro
T
Hori
Hiroko
H
Matsumoto
Chima
C
Nakamura
Jun
J
D014150:Antipsychotic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D020820:Dyskinesias / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010347:Patient Care Planning
D014150:Antipsychotic Agents